Background: The development of more sensitive HCV RNA assays might necessitate re-evaluation of the rules for stopping treatment (for example, HCV RNA negativity at week 24 during treatment with pegylated interferon-α and ribavirin for chronic hepatitis C). The aim of this study was to assess discordance between the week 24 HCV RNA test results of two PCR-based assays (Amplicor and TaqMan) and the transcription-mediated amplification (TMA) HCV RNA qualitative assay. Methods: A total of 89 week 24 samples that were negative using PCR-based assays during treatment were retested with the TMA qualitative assay to investigate discordance between tests results. All week 24 samples were HCV RNA negative by Amplicor or by TaqMan. Results: Of the 89 patients, 46 (52%) achieved sustained virological response (SVR). Viral breakthrough or relapse occurred in 43 patients (48%). All 89 HCV RNA negative week 24 samples were retested with the qualitative TMA assay. Eleven out of 89 samples had detectable HCV RNA (12%). All patients with detectable HCV RNA experienced breakthrough or relapse (negative predictive value 100%). Of the 78 patients with undetectable HCV RNA at week 24 using the TMA assay, 46 achieved SVR. This resulted in a positive predictive value (PPV) of 59% for the TMA assay compared with a PPV of 52% for the PCR-based assays. Conclusions: All patients with detectable HCV RNA at week 24 using the TMA assay eventually relapsed. On the basis of these results, the use of this more sensitive HCV RNA assay could lead to the prevention of unnecessary treatment.
occurred in 43 patients (48%). All 89 HCV RNA negative week 24 samples were retested with the qualitative TMA assay. Eleven out of 89 samples had detectable HCV RNA (12%). All patients with detectable HCV RNA experienced breakthrough or relapse (negative predictive value 100%). Of the 78 patients with undetectable HCV RNA at week 24 using the TMA assay, 46 achieved SVR. This resulted in a positive predictive value (PPV) of 59% for the TMA assay compared with a PPV of 52% for the PCR-based assays. Conclusions: All patients with detectable HCV RNA at week 24 using the TMA assay eventually relapsed. On the basis of these results, the use of this more sensitive HCV RNA assay could lead to the prevention of unnecessary treatment.
The current standard treatment for chronic hepatitis C is a 24-or 48-week regimen with pegylated interferon-α (PEG-IFN-α) and ribavirin [1] [2] [3] . This treatment regimen is monitored by determination of HCV RNA levels before, during and after HCV treatment. Quantitative HCV RNA assays are carried out to assess the viral load at baseline and at week 12. Qualitative assays are performed to determine whether HCV RNA is undetectable at week 24, at the end of treatment (EOT) and 24 weeks after EOT. Current guidelines recommend discontinuation of therapy if HCV RNA decline is <2 logs at week 12 or when HCV RNA is still detectable at week 24 of therapy. These recommendations are based on negative predictive values (NPV) of nearly 100% for a <2 log drop at week 12 and HCV RNA positivity at week 24 [3] [4] [5] [6] .
The most commonly used techniques for the detection of HCV RNA are target amplification, as applied in PCR, and transcription-mediated amplification (TMA) [7, 8] . Two PCR-based assays that are often used for the detection of HCV RNA during treatment are the COBAS ® AmpliPrep/COBAS ® Amplicor HCV test V2.0, lower limit of detection (LLOD) 20 IU/ml (Amplicor), and the COBAS ® AmpliPrep/COBAS ® TaqMan ® HCV test v1.0, LLOD 15 IU/ml (TaqMan) [9, 10] . Both tests are from Roche Diagnostics, Almere, The Netherlands. Detectable HCV RNA with these PCR-based assays at week 24 will lead to discontinuation of therapy. There is, however, a significant number of patients with undetectable HCV RNA at this time point who will eventually have a viral relapse after completion of therapy [4] . 
Introduction
The LLOD of the VERSANT ® TMA HCV RNA qualitative assay (Siemens Medical Solutions Diagnostics, Eindhoven, The Netherlands) is lower (5.3 IU/ ml) than the LLOD of the PCR-based assays (15-20 IU/ml) [11] . These differences in LLOD could lead to discordance in week 24 HCV RNA test results and, thus, to differences in PPVs. Furthermore it is unclear whether a negative test result at week 24 obtained by the TMA assay has the same NPV as a negative test result obtained by the less sensitive PCR-based assays. If NPVs are comparable, use of the most sensitive assay would reduce the PEG-IFN-α/ribavirin-related side effects and costs associated with treatment due to unnecessary continuation of HCV therapy.
For this reason, we retested week 24 HCV RNA samples that had been previously tested during antiviral therapy with the PCR-based assays Amplicor or TaqMan with a TMA HCV RNA qualitative assay. In this way we aimed to investigate discordance between test results and to determine the NPV of the TMA.
Methods

Sample selection
A total of 89 week 24 samples were included in the analysis. Week 24 samples of 77 patients were selected from a single-centre cohort of 321 patients with chronic hepatitis C treated with PEG-IFN-α/ribavirin between 2000 and 2009 [12, 13] . The remaining 12 samples were selected from a cohort study investigating continuous interferon α-2b administration in combination with ribavirin ( Figure 1 ). All selected patients received a 24, 48 or 72 week treatment regimen depending on HCV genotype, viral load, response and previous treatment. Selected patients were HCV RNA positive at week 4 and HCV RNA negative at week 24 of treatment. Serum samples dated from 2001 to 2009 and were all stored frozen at -80°C. During therapy, HCV RNA was determined using the Amplicor and TaqMan assays. Serum sample testing was performed according to the manufacturer's instructions.
Retesting HCV RNA with the VERSANT TMA HCV RNA qualitative assay
All 89 PCR-negative week 24 samples were retested with the TMA assay according to the manufacturer's instructions. The sensitivity is independent of the different HCV genotypes. The principle is based on amplification of target RNA; following amplification one detection probe is bound per RNA copy. The assay requires 500 µl plasma or serum and the LLOD is 5.3 IU/ml. The assay has a specificity of 99.6%, which minimizes the risk of false-positive results [11] .
Statistical analysis
Prediction of therapy outcome was performed using NPV and PPV. PPVs of week 24 HCV RNA negativity were calculated using all patients, including patients with undetectable HCV RNA at week 12 of treatment.
Results
Samples
A total of 89 week 24 samples were included in the analysis. Baseline characteristics of patients are summarized in Retesting with the TMA HCV RNA qualitative assay
All 77 week 24 HCV RNA samples tested with the Amplicor assay were retested with the TaqMan assay.
No discordance was found between the Amplicor and TaqMan PCR-based assays. All 89 week 24 samples were retested with the TMA assay. Of the 89 samples retested with the TMA-based assay, 11 were found to be positive for HCV RNA (12%). Two HCV RNA positive patients were treated for 24 weeks and nine patients for 48 weeks. Nine patients with detectable HCV RNA using the TMA assay had a virological relapse after treatment and two patients had a virological breakthrough during treatment. One of the nine patients who relapsed had undetectable HCV RNA 24 weeks after the EOT with the TMA assay; however, HCV RNA was detectable again 1 year after EOT. In the remaining 78 samples retested with the TMA assay HCV RNA could not be detected. Of these patients, 32 (41%) had a virological relapse and 46 (59%) achieved SVR. The minimum follow-up of these patients was at least 1 year after EOT. The PPV of undetectable HCV RNA at week 24 determined by the TMA assay was 59% (46/78) compared with 52% (46/89) for the PCR-based assays ( Table 2 ). The NPV of a positive HCV RNA test result for virological relapse was 100% (11/11).
Discussion
This study investigates discordance between the TMA HCV RNA qualitative assay with an LLOD of 5.3 IU/ ml and two PCR-based assays with a minimal follow-up of at least 1 year. In this cohort we found discordance in 12% of the test results. All patients with detectable HCV RNA at week 24 using the TMA assay experienced a viral relapse or breakthrough after or during treatment. Eventually all patients became HCV RNA positive; thus, the NPV of detectable HCV RNA at week 24 using the TMA assay was 100% in this study. Furthermore, the PPV of a negative TMA test result was somewhat higher than the PPV of a negative PCR test result (59% versus 52%), although we should mention that these PPVs are based on all patients including patients with undetectable HCV RNA at week 12.
Earlier studies reported detectable HCV RNA by TMA assay in EOT samples that were HCV RNA negative when tested with PCR-based assays. With the exception of a few cases, all patients with a positive TMA test result had a viral relapse after treatment cessation [14] [15] [16] [17] .
Morishima and colleagues [18] retested PCR-negative on-treatment HCV RNA samples with the TMA assay (at that time the LLOD of the TMA assay was 9.6 IU/ ml). They found a discordance of 19.9% between the PCR-based assay and the TMA assay in week 24 samples. Six patients (9%) with a PCR-negative and a TMApositive result at week 24 eventually achieved an SVR; however, these patients had a negative TMA test result on week 20 of therapy. Patients with detectable HCV RNA at both time points all experienced viral relapse. The authors concluded that a single positive TMA test result could not rule out SVR. However, the NPV of a positive TMA test result was still high: 91%. Furthermore, they mention in their discussion that a delayed relapse after 24 weeks of follow-up could not be ruled out. Another study of Morishima and colleagues [19] showed that some PCR-negative/TMA-positive samples were TMA-negative on repeat testing. Discordant TMA test results occurred in patients with HCV RNA levels fluctuating around the LLOD and were strongly associated with viral breakthrough or relapse.
In conclusion, on the basis of these results, the NPV of a positive TMA test result on week 24 is still 100%. The use of the more sensitive TMA assay could lead to the prevention of unnecessary treatment, thereby reducing the associated side effects and costs.
